LIXTE.jpg
LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
03 août 2021 09h25 HE | Lixte Biotechnology Holdings, Inc.
A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationale for a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently...
LIXTE.jpg
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
22 juil. 2021 09h25 HE | Lixte Biotechnology Holdings, Inc.
Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving...
LIXTE.jpg
Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
13 juil. 2021 09h25 HE | Lixte Biotechnology Holdings, Inc.
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne...
LIXTE.jpg
Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
28 avr. 2021 09h35 HE | Lixte Biotechnology Holdings, Inc.
Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc....
LIXTE.jpg
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
13 avr. 2021 09h35 HE | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: LIXT), a clinical-stage drug discovery company developing...